Abstract
Caprolactam urea 1, identified as a weak Factor Xa inhibitor screening hit (IC50 = 16 μM), served as the starting point for a limited parallel-synthesis driven SAR study to improve potency. Remarkably, the corresponding thiourea analog 8c (IC50 = 0.11 μM) was 145-fold more potent against Factor Xa compared to 1. In general, caprolactam analogs containing a thiourea linker were significantly more potent than their corresponding urea counterparts, and it is hypothesized that this is partly due to a conformational preference of the thiourea linkage which facilitates binding of the terminal groups of the inhibitors to the Factor Xa S1/S4 pockets. Analog 8c was selective against a panel of related serine proteases. Upon intra-duodenal administration in rats, 8c dose-dependently increased prothrombin time ex vivo, and when dosed i.v., it demonstrated efficacy in a rat model of venous thrombosis. This thiourea lead series formed the basis for follow-on investigations to discover potent drug-like Factor Xa inhibitors using the caprolactam scaffold but employing suitable thiourea surrogates.
Keywords: Factor Xa, FXa inhibitor, caprolactam, serine protease
Letters in Drug Design & Discovery
Title: Initial Structure-Activity Relationships for a Caprolactam-based Series of Neutral Factor Xa Inhibitors: Lead Identification
Volume: 2 Issue: 8
Author(s): Gregory S. Bisacchi, Philip D. Stein, Jack Z. Gougoutas, Karen S. Hartl, R. Michael Lawrence, Eddie Liu, Andrew Pudzianowski, William A. Schumacher, Doree Sitkoff, Thomas E. Steinbacher, James Sutton, Zhaoxiao Zhang and Steven M. Seiler
Affiliation:
Keywords: Factor Xa, FXa inhibitor, caprolactam, serine protease
Abstract: Caprolactam urea 1, identified as a weak Factor Xa inhibitor screening hit (IC50 = 16 μM), served as the starting point for a limited parallel-synthesis driven SAR study to improve potency. Remarkably, the corresponding thiourea analog 8c (IC50 = 0.11 μM) was 145-fold more potent against Factor Xa compared to 1. In general, caprolactam analogs containing a thiourea linker were significantly more potent than their corresponding urea counterparts, and it is hypothesized that this is partly due to a conformational preference of the thiourea linkage which facilitates binding of the terminal groups of the inhibitors to the Factor Xa S1/S4 pockets. Analog 8c was selective against a panel of related serine proteases. Upon intra-duodenal administration in rats, 8c dose-dependently increased prothrombin time ex vivo, and when dosed i.v., it demonstrated efficacy in a rat model of venous thrombosis. This thiourea lead series formed the basis for follow-on investigations to discover potent drug-like Factor Xa inhibitors using the caprolactam scaffold but employing suitable thiourea surrogates.
Export Options
About this article
Cite this article as:
Bisacchi S. Gregory, Stein D. Philip, Gougoutas Z. Jack, Hartl S. Karen, Lawrence Michael R., Liu Eddie, Pudzianowski Andrew, Schumacher A. William, Sitkoff Doree, Steinbacher E. Thomas, Sutton James, Zhang Zhaoxiao and M. Seiler Steven, Initial Structure-Activity Relationships for a Caprolactam-based Series of Neutral Factor Xa Inhibitors: Lead Identification, Letters in Drug Design & Discovery 2005; 2 (8) . https://dx.doi.org/10.2174/157018005774717316
DOI https://dx.doi.org/10.2174/157018005774717316 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Disease - Current Knowledge and Future Prospects
Current Genomics Engineered Nanoparticles in Cancer Therapy
Recent Patents on Drug Delivery & Formulation Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights
Current Pharmaceutical Design 3D-QSAR Studies of HDAC6 Inhibitors Using Docking-Based Alignment
Letters in Drug Design & Discovery A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets Withdrawal Notice: Design and Development of Key Chain Held Insulin injectable device
Current Diabetes Reviews Viral Entry Inhibitors Targeting Six-Helical Bundle Core against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins
Current Medicinal Chemistry Design and Synthesis of Novel 2- Substituted Benzothiazole Compounds as PTP1B Inhibitors
Letters in Drug Design & Discovery Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada
Current Drug Safety An Efficient and Environmentally Benign Four-component Domino Protocol for Synthesis of Spirooxindoles Spiroannulated with Fused Heterosystems of Privileged Heterocycles
Current Bioactive Compounds Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Neurological Manifestations of COVID-19 and the Importance of Magnetic Resonance Imaging
CNS & Neurological Disorders - Drug Targets Intrahepatic Cholestasis of Pregnancy and Bile Acids Induced Lung Injury in Newborn Infants
Current Pediatric Reviews Acetogenins as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Functionalized Photocatalytic Nanocoatings for Inactivating COVID-19 Virus Residing on Surfaces of Public and Healthcare Facilities
Coronaviruses Meet Our Editorial Board Member
Medicinal Chemistry Meet Our Editorial Board Member
Pharmaceutical Nanotechnology Self-Organizing Maps for the Classification of Gallic Acylate Polyphenols as HSV-1 Inhibitors
Medicinal Chemistry